Natera Inc (NTRA) · Other

Biogen Inc (BIIB) · Other

U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.

5/24/2026, 12:00:00 AM

Exelixis Inc (EXEL) · Earnings Release

Exelixis is expected to report its Q1 2026 earnings on or around May 12, 2026, and analysts forecast EPS of approximately $0.73-$0.76; high importance reflects potential volatility from earnings surprises, forecasted and scheduled.

5/12/2026, 12:00:00 AM

Eli Lilly and Co (LLY) · Earnings Release

Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.

4/30/2026, 12:00:00 AM

Bristol-Myers Squibb Co (BMY) · Earnings Release

Bristol Myers Squibb Q1 2026 results conference call is scheduled for 2026-04-30; as the next earnings catalyst following the strong Q4 2025 outlook, a multi-percent share move is reasonably expected based on typical earnings volatility scheduled.

4/30/2026, 12:00:00 AM

Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release

Teva is scheduled to release its financial results for the first quarter of 2026 before the market opens on April 29, 2026, followed by a conference call with management; a 5% price impact is estimated for this earnings release, scheduled.

4/29/2026, 12:00:00 AM

AbbVie Inc (ABBV) · Earnings Release

First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.

4/24/2026, 12:00:00 AM